Good
Mostly Aligned
Patient Risk:
Low
Summary
Most provided clinical indication and dosage form claims match the supplied label excerpts. However, other claims (manufacturer/program and patent/exclusivity assertions) are absent from the label, and label safety-critical sections (contraindications, warnings, dosing/administration details) were not assessed.
Category Scores
Accurate Statements
Opzelura (ruxolitinib) es una crema.
Supported by 3 DOSAGE FORMS AND STRENGTHS and 11 DESCRIPTION (OPZELURA (ruxolitinib) cream...).
Opzelura se utiliza para tratar la dermatitis atópica.
Supported by 1 INDICATIONS AND USAGE (1.1 Atopic Dermatitis).
Opzelura se utiliza para tratar la vitíligo.
Supported by 1 INDICATIONS AND USAGE (1.2 Nonsegmental Vitiligo).
Unsupported Statements
El fabricante de Opzelura, Incyte, ofrece el programa "Incyte CARES" para ayudar a pacientes elegibles a reducir sus gastos de bolsillo, incluyendo copagos y deducibles.
Absent from the provided labeling sections.
Opzelura es fabricado por Incyte Corporation.
Manufacturer attribution is not present in the supplied label excerpts.
Las patentes asociadas con ruxolitinib (ingrediente activo de Opzelura) tienen fechas de vencimiento variables y pueden estar sujetas a litigios, lo que podría afectar la exclusividad del mercado.
Patent/exclusivity or litigation information is not present in the supplied label excerpts.
Contradictions
Important Omissions
No evaluation of label safety-critical content (e.g., contraindications, warnings/precautions, boxed warnings if any, drug interactions, and use in specific populations such as pregnancy/lactation/pediatrics), nor detailed dosing/administration constraints (e.g., frequency/maximum treatment area/duration) from section 2 DOSAGE AND ADMINISTRATION.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claims evaluated here concern dosage form and indications; unsupported claims are promotional/manufacturer/patent assertions and are not, by themselves, dosing/safety instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided label excerpts (patient cost program, manufacturer attribution, patent/exclusivity discussion).
Suggested Improvement
Limit claims to label-supported content; when addressing safety or dosing, evaluate and cite the specific sections (2, 4, 5, 8, and interactions) rather than only indications and dosage form.